Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Richard B BanatiS B Blunt

Abstract

The cause and mechanism of neuronal cell death in the substantia nigra of patients with Parkinson's disease (PD) are unknown. There is also controversy about whether the cell death results from a single event followed by cell loss consistent with aging or whether there is an ongoing pathologic process. Using postmortem tissue obtained from the Parkinson's Disease Society Brain Tissue Bank in London, we have sought to establish whether apoptosis, or more specifically DNA fragmentation of neurons, is a prominent feature of nigral pathology. In addition, we have studied microglial activation in the substantia nigra as an indicator of ongoing pathology using the highly sensitive markers CR3/43 and EBM11. Reactive astrocytes have been assessed using immunostaining for glial fibrillary acidic protein (GFAP). Ten patients with pathologically proven PD were studied. In all cases, regardless of disease duration, severity, drug treatment, or age of the patient, there was no evidence of apoptosis in the substantia nigra as assessed by in situ end-labeling of DNA fragments using biotinylated dUTP and terminal deoxynucleotidyl transferase (TdT). In contrast, a case of multiple system atrophy (MSA) served as a positive control for the techni...Continue Reading

References

Oct 1, 1991·Brain : a Journal of Neurology·J M Fearnley, A J Lees
Jun 3, 1989·Lancet·A H SchapiraC D Marsden
Nov 21, 1987·Lancet·D T DexterC D Marsden
Jan 1, 1971·The American Journal of Cardiology·E G Dimond
Jan 1, 1980·International Review of Cytology·A H WyllieA R Currie
Apr 1, 1994·Journal of Cardiothoracic and Vascular Anesthesia·V UmbrainF Camu
Nov 1, 1994·Journal of Neuropathology and Experimental Neurology·A MigheliD Schiffer
Sep 1, 1995·Journal of Neuropathology and Experimental Neurology·J Gehrmann, R B Banati
Jan 1, 1994·Developmental Neuroscience·R B Banati, M B Graeber
Jan 1, 1995·Acta Neuropathologica·H LassmannH M Wisniewski
Aug 1, 1994·Neuropathology and Applied Neurobiology·M B GraeberP Mehraein
Sep 17, 1994·Lancet·P Jenner

❮ Previous
Next ❯

Citations

Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·E C HirschW C Olanow
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·U WüllnerT Klockgether
Apr 1, 2003·Annals of Neurology·Peter Jenner
Apr 1, 2003·Annals of Neurology·William G TattonNadine Tatton
Jul 20, 2001·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·J K Andersen
Nov 25, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·A E KingsburyO J Foster
Sep 1, 2004·Cell and Tissue Research·Peter Teismann, Jörg B Schulz
Sep 15, 2004·Cell and Tissue Research·Jörg B Schulz, Björn H Falkenburger
Nov 30, 2010·Bulletin of Experimental Biology and Medicine·G M YusubalievaV P Chekhonin
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Krishnan Sriram, James P O'Callaghan
Jul 6, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Sara L Montgomery, William J Bowers
Sep 1, 2012·Molecular Neurobiology·Toru YasudaHideki Mochizuki
May 12, 2005·Parkinsonism & Related Disorders·Etienne C HirschAndreas Hartmann
Dec 7, 2002·Brain Research·Maria J MartíEduard Tolosa
Nov 14, 2002·Neurotoxicology·Maryka Quik, Jennifer M Kulak
Jul 9, 2002·Brain Research. Developmental Brain Research·Shuang ZhengBruce D Howard
Mar 27, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Nirit LevDaniel Offen
Jan 4, 2001·Neuroscience Letters·K S McNaught, P Jenner
Mar 12, 2003·Toxicology Letters·Olaf Eberhardt, Jörg B Schulz
Jun 1, 1999·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A M Bonnet, J L Houeto
Aug 30, 2002·Neurotoxicology and Teratology·K L DoubleM Gerlach
Jul 2, 2008·Parkinsonism & Related Disorders·C KnottG Stern
Mar 27, 2003·Trends in Molecular Medicine·Ari Barzilai, Eldad Melamed
May 13, 2009·Journal of Proteome Research·Ashley D ReynoldsHoward E Gendelman
Dec 5, 2009·Cell Death and Differentiation·M D'AmelioF Cecconi
May 19, 2011·Nature Reviews. Neuroscience·Timothy J CollierJeffrey H Kordower
Oct 3, 2002·Journal of Neurochemistry·Laurel M BolinDonato Di Monte
Oct 3, 2002·Journal of Neurochemistry·Allen S MandirTed M Dawson
Aug 28, 2001·Neuroreport·S Love
Jun 18, 2002·Journal of Cellular and Molecular Medicine·K A Jellinger
Aug 16, 2006·Neuro-degenerative Diseases·Pawel KermerMathias Bähr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis